Presentation by ProMIS Chief Development Officer, Dr. Johanne Kaplan, on PMN310 Best in Class Product Profile

ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and OTCQB (ticker symbol: ARFXF).ProMIS is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).

Traded on the Toronto Stock Exchange (TSX), under the symbol PMN.TO, and on the OTCQB under the symbol ARFXF